Fibroblasts from Wharton's Jelly
A commonly used label that is imprecise — Wharton's jelly yields mesenchymal stromal cells, not classical dermal fibroblasts.
Investigational
What it actually is
Wharton's jelly is the gelatinous connective tissue surrounding the umbilical vessels. Cells cultured from it are adherent and spindle-shaped, and by ISCT criteria they are mesenchymal stromal cells. 'Fibroblast' is a morphological description, not a defined regulatory or biological identity — the two words are used interchangeably in marketing and should not be.
Where it comes from
Allogeneic, from umbilical cords donated after full-term delivery. The tissue is otherwise discarded, is collected without any risk to donor or infant, and yields cells that proliferate faster and senesce later than adult-derived cells — the main practical argument for perinatal sourcing.
How it is made — and what can go wrong
The cord is dissected, Wharton's jelly separated from vessels and amniotic covering, then explanted or enzymatically digested and expanded. Because the tissue contains several compartments, dissection technique meaningfully affects which cells end up in the flask. Two laboratories can produce different products from the same starting material.
Regulatory status
No approved Wharton's jelly medicine. Culture-expanded cells are substantially manipulated, which under EU rules makes the resulting product an advanced therapy medicinal product requiring a manufacturing authorisation — a materially higher bar than a tissue establishment permit. This distinction is the one most often blurred in clinic marketing.
What the evidence shows
Registered trials exist across several indications, predominantly early phase. Where these cells are marketed for aesthetic use, the evidence base is weaker than the marketing implies, and outcome measures are frequently subjective.
Limits worth knowing
Terminology is the first problem: verify whether the product meets the ISCT mesenchymal criteria or is simply called a fibroblast. Donor variability applies as it does to all perinatal MSC products.
What this could actually be used for
Mesenchymal cells taken from the connective tissue of the umbilical cord (Wharton’s jelly). Biologically young, easy to expand to large numbers, and collected from material that is otherwise discarded, without any procedure performed on a donor.
The appeal is logistical and immunological before it is mechanistic: an off-the-shelf, well-tolerated mesenchymal source without the age-related decline of an older patient’s own cells. What the cells then do is the ordinary mesenchymal repertoire — the argument is about supply and quality, not about a different mechanism.
Where a patient’s own cells are poor 10 studies registered
Older and chronically ill patients have fewer mesenchymal cells and less potent ones. If a therapy depends on secretion, harvesting from a patient whose cells secrete badly puts a ceiling on the result before treatment starts. A young donor source removes that ceiling, and that is the whole argument. All cell therapy research registered for this condition →
Repeat dosing 8 studies registered
Banked, expandable cells make several doses practical. A marrow harvest per dose does not scale, and single-dose study designs may be testing the wrong schedule for a mechanism that is transient by nature. All cell therapy research registered for this condition →
Immunologically sensitive settings
Lower expression of the surface markers that trigger rejection is the stated reason for using these cells across donor boundaries. That is a claim about tolerance rather than invisibility — repeat allogeneic dosing is exactly where it would be tested, and largely has not been.
Neonatal and paediatric conditions
Perinatal tissue is studied in complications of prematurity, where an adult autologous source does not exist and the timescale rules out expanding a patient’s own cells anyway.
Where it stops. Every mesenchymal caveat applies here, plus donor-to-donor variability that banking reduces but does not remove. ‘Young cells’ describes the starting material, not the finished product.
What the registry actually shows for this cell type
Our own count of every study registered on ClinicalTrials.gov under this cell type, retrieved 2026-09-04. A registration is a declaration of intent, not a result — which is why the status column matters more than the total does.
| Status in the registry | Studies | Share |
|---|---|---|
| Completed | 29 | 40% |
| Status not updated by sponsor | 26 | 36% |
| Recruiting now | 6 | 8% |
| Not yet recruiting | 5 | 7% |
| Terminated early | 4 | 5% |
| Active, closed to entry | 2 | 3% |
| Withdrawn before enrolling | 1 | 1% |
| All registered studies | 73 | 100% |
Reading it: 5 studies stopped before finishing — terminated, withdrawn or suspended, 7% of the total; 9 studies carry no assigned trial phase, meaning they sit outside the phased development path that leads to an approved medicine; 22 studies reached Phase 2 or later, against 42 studies still at Phase 1 or earlier; 26 records have not had a status update from the sponsor and may be dormant.
The directions above describe where the biology points and where research has been registered. They are not claims that any of it works, not evidence of benefit, and not a treatment recommendation. Counts are our own extraction from the ClinicalTrials.gov API, retrieved 2026-09-04; the queries behind them are published with the dataset so that anyone can repeat the count.
What to ask before agreeing to anything
- Does the product meet ISCT mesenchymal stromal cell criteria — plastic adherence, marker panel, trilineage differentiation?
- Which part of the cord was used, and how was the tissue separated?
- Is the manufacturer holding an ATMP manufacturing authorisation, or only a tissue establishment permit?
- What evidence exists for this specific indication, from a product manufactured this way?
Sources behind the numbers on this page
- PubMed — Fibroblasts from Wharton's Jelly
- ClinicalTrials.gov — registered studies
- EMA — advanced therapy medicinal products
- FDA — cellular and gene therapy products
Study counts above are our own extraction from ClinicalTrials.gov; the links let you reproduce them. Not medical advice, and not an assessment of whether any treatment is appropriate for you.